BioXcel Turns To Commercialization With Positive Phase III Data In Agitation

 
• By Jessica Merrill

The company is developing a sublingual thin film of dexmedetomidine that could be used to treat agitation in a wide range of indications after planned initial launches in schizophrenia and bipolar disorder.

soccer ball in goal
BioXcel scored in two Phase III trials • Source: Shutterstock

More from Strategy

More from Business